1. Generics Bulletin
  2. >>Products
  3. >>Generics

California Proceeds With Manufacturing Its Own Generics

As Generic Drug Pricing Bill Gets Approval

 
• By Akriti Seth

With the legislature’s green light on California’s Generic Drug Pricing Bill, the state aims to manufacture generics while addressing shortages in the prescription drug market, expanding access to life-saving generic prescription drugs and improving patient health outcomes and overall public health. 

Made_In_California
California is to partner with drug companies on a broad range of generics • Source: Shutterstock

California is set to become the first US state to manufacture its own line of generic drugs after the state legislature approved the Generic Drug Pricing Bill, aimed to increase competition, lower prices and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs and to increase patient access to affordable drugs.

California will now be able to partner with drug companies to manufacture generic prescription drugs. The bill requires the state...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By Dean Rudge

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.